본문 바로가기

Machine Learning Model to Predict Pseudoprogression Versus Progression in Glioblastoma Using MRI: A Multi-Institutional Study (KROG 18-07)

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q3
저널
CANCERS12(9) · pp.1 · 2020
피인용
Web of Science 31Scopus 33
FWCI (Scopus)
0
JCR IF
JCR 2019 6.126
ISSN
2072-6694

저자

  1. Jang, Bum-Sup제1저자Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, 13620, Korea;
  2. Park, Andrew J.Artificial Intelligence Research and Development Laboratory, SELVAS AI Incorporation, Seoul, 08594, Korea;
  3. Jeon, Seung HyuckGraduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Korea;
  4. Kim, Il HanDepartment of Radiation Oncology, Seoul National University Hospital, Seoul, 03080, Korea;
  5. Lim, Do HoonDepartment of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 06351, Korea;
  6. Park, Shin-HyungDepartment of Radiation Oncology, School of Medicine, Kyungpook National University, Daegu, 41944, Korea;
  7. 이주혜Department of Radiation Oncology, Pusan National University Hospital, Busan, 49241, Korea;
  8. Chang, Ji HyunDepartment of Radiation Oncology, Seoul National University Hospital, Seoul, 03080, Korea;
  9. Cho, Kwan HoThe Proton Therapy Center, Research Institute and Hospital, National Cancer Center, Goyang, 10408, Korea;
  10. Kim, Jin HeeDepartment of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, 42601, Korea;
  11. Sunwoo, LeonardDepartment of Radiology, Seoul National University Bundang Hospital, Seongnam, 13620, Korea;
  12. Choi, Seung HongDepartment of Radiology, Seoul National University Hospital, Seoul, 03080, Korea;
  13. Kim, In Ah교신저자Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, 13620, Korea;

초록

Simple Summary Even after the introduction of a standard regimen consisting of concurrent chemoradiotherapy and adjuvant temozolomide, patients with glioblastoma multiforme mostly experience disease progression. Clinicians often encounter a situation where they need to distinguish progressive disease from pseudoprogression after treatment. We tried to investigate the feasibility of machine learning algorithm to distinguish pseudoprogression from progressive disease. In multi-institutional dataset, the developed machine learning model showed an acceptable performance. This algorithm involving MRI data and clinical features could help making decision during patients' disease course. For the practical use, we calibrated the machine learning model to offer the probability of pseudoprogression to clinicians, then we constructed the web-based user interface to access the model. Some patients with glioblastoma show a worsening presentation in imaging after concurrent chemoradiation, even when they receive gross total resection. Previously, we showed the feasibility of a machine learning model to predict pseudoprogression (PsPD) versus progressive disease (PD) in glioblastoma patients. The previous model was based on the dataset from two institutions (termed as the Seoul National University Hospital (SNUH) dataset,N= 78). To test this model in a larger dataset, we collected cases from multiple institutions that raised the problem of PsPD vs. PD diagnosis in clinics (Korean Radiation Oncology Group (KROG) dataset,N= 104). The dataset was composed of brain MR images and clinical information. We tested the previous model in the KROG dataset; however, that model showed limited performance. After hyperparameter optimization, we developed a deep learning model based on the whole dataset (N= 182). The 10-fold cross validation revealed that the micro-average area under the precision-recall curve (AUPRC) was 0.86. The calibration model was constructed to estimate the interpretable probability directly from the model output. After calibration, the final model offers clinical probability in a web-user interface.

키워드

machine learningglioblastomaradiotherapypseudoprogressionMGMT PROMOTER METHYLATIONHIGH-GRADE GLIOMASADJUVANT TEMOZOLOMIDERESPONSE ASSESSMENTTUMOR PROGRESSIONMALIGNANT GLIOMARADIOTHERAPYFEATURESCRITERIACONCOMITANT

식별자

Scopus EID
2-s2.0-85091671403
WoS UID
000579934400001